Suppr超能文献

再次暴露于赖诺普利后血管紧张素转换酶抑制剂(ACEI)诱发的血管性水肿:一例报告及临床综述

Angiotensin-Converting Enzyme Inhibitor (ACEI)-Induced Angioedema After Re-exposure to Lisinopril: A Case Report and Clinical Review.

作者信息

Tou Leila C, DeMott Jacob D, Palacios José M

机构信息

Department of Internal Medicine, Wright State University Boonshoft School of Medicine, Dayton, USA.

出版信息

Cureus. 2025 Aug 11;17(8):e89784. doi: 10.7759/cureus.89784. eCollection 2025 Aug.

Abstract

Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema is an uncommon but potentially life-threatening adverse effect that can occur unpredictably, even after prolonged use. Prompt recognition and appropriate management are essential. We present the case of a 54-year-old Caucasian male with a history of ACEI-induced angioedema who developed isolated lingual swelling after re-exposure to lisinopril. His symptoms were unresponsive to antihistamines, corticosteroids, and epinephrine but resolved with supportive care following ACEI discontinuation. This case underscores the risk of recurrent angioedema following ACEI re-exposure and reinforces the recommendation for lifelong avoidance of ACEIs in patients with a prior diagnosis of ACEI-induced angioedema. Angiotensin receptor blockers (ARBs), which carry a lower risk of angioedema, may serve as preferred alternatives in high-risk patients. Patient education remains critical to preventing recurrence.

摘要

血管紧张素转换酶抑制剂(ACEI)诱发的血管性水肿是一种罕见但可能危及生命的不良反应,即使在长期使用后也可能不可预测地发生。迅速识别和适当处理至关重要。我们报告一例54岁的白种男性病例,该患者有ACEI诱发血管性水肿病史,再次接触赖诺普利后出现孤立性舌肿胀。他的症状对抗组胺药、皮质类固醇和肾上腺素均无反应,但在停用ACEI后通过支持治疗得以缓解。该病例强调了再次接触ACEI后血管性水肿复发的风险,并强化了对既往诊断为ACEI诱发血管性水肿的患者终身避免使用ACEI的建议。血管紧张素受体阻滞剂(ARB)诱发血管性水肿的风险较低,可作为高危患者的首选替代药物。患者教育对于预防复发仍然至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75b7/12421465/2f707827a317/cureus-0017-00000089784-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验